In the current study, we applied DCLK1‐IN‐1 to targeting DCLK1, and found that DCLK‐IN‐1 suppressed 5‐fluorouracil resistant CRC cells by inhibiting CCAR1/β‐catenin pathway‐mediated cancer stemness. The gene discussed is DCLK1; the disease is cancer.